Moffitt Cancer Center Logo
 

Amod Sarnaik, MD

Where You Are:

Amod Sarnaik, MD

Surgery

For Consultation Requests or Referrals: (813) 745-8582

 
 

BOARD CERTIFICATION:
          •  Surgery

FELLOWSHIP:
          •  University of South Florida - Surgical Oncology Fellow, Moffitt Cancer Center
          •  University of Cincinnati - Howard Hughes Investigational Postdoctoral Fellow, Molecular Genetics

RESIDENCY:
          •  University of Cincinnati - Surgery
          •  University of Cincinnati - Surgery

MEDICAL SCHOOL:
          •  University of Michigan - MD

  • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec;31(34):4311-4318. Pubmedid: 24145345. Pmcid: PMC3837092.

  • Radvanyi L, Pilon-Thomas S, Peng W, Sarnaik A, Mul? JJ, Weber J, Hwu P. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Letter. Clin Cancer Res. 2013 Oct;19(19):5541. Pubmedid: 24048330.

  • Zager JS, Sarnaik AA, Gibney GT, Kudchadkar RR. Recent advances in the treatment of melanoma. Cancer Control. 2013 Oct;20(4):244-245. Pubmedid: 24077400.

  • Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2013 Sep;2(9):e25581. Pubmedid: 24319633.

  • Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013 Sep;8(4):e60031. Pubmedid: 23560068. Pmcid: PMC3613355.

  • Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 2013 Jul;8(7):e68561. Pubmedid: 23874673.

  • Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, Sarnaik AA, Pilon-Thomas S. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother. 2013 Jun;62(6):1083-1091. Pubmedid: 23604104. Pmcid: PMC3666559.

  • Deneve JL, Turaga KK, Marzban SS, Puleo CA, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS. Single-institution outcome experience using AlloDerm? as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. Am Surg. 2013 May;79(5):476-482. Pubmedid: 23635582.

  • Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med. 2013 Apr;10:146. Pubmedid: 22788688. Pmcid: PMC3527361.

  • Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Mar;14(3):211-220. Pubmedid: 23354483. Pmcid: PMC3578019.

  • Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA. Immunotherapy for gastrointestinal malignancies. Cancer Control. 2013 Jan;20(1):32-42. Pubmedid: 23302905.

  • Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol. 2012 Dec;189(11):5147-5154. Pubmedid: 23100512. Pmcid: PMC3505990.

  • Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012 Nov;19(12):3888-3895. Pubmedid: 22864798.

  • Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mul? JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012 Oct;35(8):615-620. Pubmedid: 22996367.

  • Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, Wayne Cruse C, Sarnaik AA, Puleo C, Sondak VK, Zager JS. Sentinel Node Biopsy is Indicated for Thin Melanomas??0.76?mm. Ann Surg Oncol. 2012 Oct;19(11):3335-3342. Pubmedid: 22766986.

  • Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May;18(9):2502-2514. Pubmedid: 22351686. Pmcid: PMC3398738.

  • Sondak VK, Sarnaik AA. Minimizing Morbidity while Preserving Outcome after Inguinal Lymphadenectomy: Navigating between Scylla and Charybdis. Ann Surg Oncol. 2011 Apr;18(4):909-911. Pubmedid: 21246401.

  • Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin M, Weber JS. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011 Feb;17(4):896-906. Pubmedid: 21106722. Pmcid: PMC3041838.

  • Sarnaik AA, Meade T, King J, Acs G, Hoover S, Cox CE, Carter WB, Laronga C. Adenoid cystic carcinoma of the breast: a review of a single institution's experience. Breast J. 2010 Mar-Apr;16(2):208-210. Pubmedid: 20030648.

  • Sarnaik AA, Zager JS, Cox LE, Ochoa TM, Messina JL, Sondak VK. Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma <= 1 cm Is Not Justified. J Clin Oncol. 2010 Jan;28(1):e7-e7. Pubmedid: 19933899.

  • Sarnaik AA, Lien MH, Nghiem P, Bichakjian CK. Clinical recognition, diagnosis, and staging of merkel cell carcinoma, and the role of the multidisciplinary management team. Curr Probl Cancer. 2010 Jan;34(1):38-46. Pubmedid: 20371073.

  • Sarnaik AA, Puleo CA, Zager JS, Sondak VK. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control. 2009 Jul;16(3):240-247. Pubmedid: 19556964.

  • Qian J, Sarnaik AA, Bonney TM, Keirsey J, Combs KA, Steigerwald K, Acharya S, Behbehani GK, Barton MC, Lowy AM, Groden J. The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology. 2008 Aug;135(1):152-162. Pubmedid: 18474248. Pmcid: PMC2832605.

  • Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep. 2007 Sep;9(5):417-427. Pubmedid: 17706171.

  • Sarnaik AA, Sussman JJ, Ahmad SA, Lowy AM. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Surg Oncol Clin N Am. 2003 Jul;12(3):849-863. Pubmedid: 14567036.

  • Sarnaik AA, Saad AG, Mutema GK, Martin SP, Attar A, Lowy AM. Osteoclast-like giant cell tumor of the pancreas associated with a mucinous cystadenocarcinoma. Surgery. 2003 Jun;133(6):700-701. Pubmedid: 12796742.

  • Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 15(3):169-173. Pubmedid: 19556898.

Dr. Amod Sarnaik is a surgical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and a member of the Experimental Therapeutics Program.  He is an assistant professor of oncology and surgery at the University of South Florida.
Dr. Sarnaik's primary research interest involves investigation of novel immunotherapeutic treatments for melanoma.  This includes tumor-based vaccines, immune-activating antibodies, targeted inhibition of oncogenic proteins and autologous T-cell therapy. His clinical interests focus on the surgical treatment of melanoma and other cutaneous-based skin cancers, sentinel lymph node biopsy techniques, and minimizing surgically-related morbidities.
Dr. Sarnaik received his undergraduate degree from Harvard University and his medical degree from the University of Michigan School of Medicine.  He completed postgraduate training at the University of Cincinnati, OH, where he served two residencies in surgery and was chief resident. He also completed a Howard Hughes investigational postdoctoral fellowship in molecular genetics, and in 2009 Dr. Sarnaik completed a surgical oncology fellowship at Moffitt Cancer Center.

His research has been published in a number of professional medical journals.